Bicara Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bicara Therapeutics Inc (BCAX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Bicara Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bicara Therapeutics Inc | - | - | - | Yes |
| High-Confidence Competitors (13) | ||||
| Similar-Size Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BCAX Stock Performance relative to its Competitors
BCAX Stock Performance relative to High-Confidence Competitors
BCAX Stock Performance relative to Similar-Size Competitors
Bicara Therapeutics Inc's Comment on Competition and Industry Peers
Bicara Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Exelixis, Inc. | Named by the company | 85% |
| iTeos Therapeutics Inc. | Named by the company | 85% |
| Pfizer Inc. | Named by the company | 85% |
| Beigene, Ltd. | Named by the company | 85% |
| Inhibrix Biosciences, Inc. | Named by the company | 85% |
| Merck & Co | Named by the company | 85% |
| Immutep, Inc. | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Eli Lilly | Named by the company | 85% |
| Iovance Biotherapeutics, Inc. | Named by the company | 85% |
| Merus N.V. | Named by the company | 85% |
| ALX Oncology Holdings, Inc. | Named by the company | 85% |
| Incyte Corporation | Named by the company | 85% |
| Kura Oncology, Inc. | Named by the company | 85% |
| Pyxis Oncology Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bicara Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.